According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Mira Pharma's investigational drug SKNY-1 has demonstrated promising pharmacokinetic characteristics in preclinical studies.

This compound exhibits good bioavailability, meaning it can be effectively absorbed into the systemic circulation after oral administration. More importantly, research data reveal that SKNY-1 demonstrates strong exposure levels in its target organs—the brain and the liver. This high concentration distribution in critical tissues provides a significant pharmacological foundation for its potential efficacy against central nervous system or liver-related diseases. Based on its favorable pharmacokinetic profile, especially its prolonged duration of action in vivo, SKNY-1 shows promise for once-daily dosing. If this straightforward dosing regimen is confirmed in subsequent clinical development, it will significantly improve patient medication adherence, becoming a major competitive advantage for this drug. The positive preclinical data disclosed through SEC filings provide official endorsement for the progress of Mira Pharma’s R&D project and offer the latest scientific evidence for investors interested in the company’s future development.